

# Cytoskeleton protein Filamin A is required for efficient Somatostatin receptor type 2 internalization and recycling through Rab5 and Rab4 sorting endosomes in tumor somatotroph cells

Treppiedi, Donatella; Mangili, Federica; Giardino, Elena; Catalano, Rosa; Locatelli, Marco; Lania, Andrea; Spada, Anna; Arosio, Maura; Calebiro, Davide; Mantovani, Giovanna; Peverelli, Erika

DOI:  
[10.1159/000503791](https://doi.org/10.1159/000503791)

License:  
None: All rights reserved

*Document Version*  
Peer reviewed version

*Citation for published version (Harvard):*

Treppiedi, D, Mangili, F, Giardino, E, Catalano, R, Locatelli, M, Lania, A, Spada, A, Arosio, M, Calebiro, D, Mantovani, G & Peverelli, E 2019, 'Cytoskeleton protein Filamin A is required for efficient Somatostatin receptor type 2 internalization and recycling through Rab5 and Rab4 sorting endosomes in tumor somatotroph cells', *Neuroendocrinology*. <https://doi.org/10.1159/000503791>

[Link to publication on Research at Birmingham portal](#)

**Publisher Rights Statement:**  
Checked for eligibility: 09/10/2019

This is the peer-reviewed but unedited manuscript version of the following article: Treppiedi, D., Mangili, F., Giardino, E., Catalano, R., Locatelli, M., Lania, A., Spada, A., Arosio, M., Calebiro, D., Mantovani, G. and Peverelli, E., 2019. Cytoskeleton protein Filamin A is required for efficient Somatostatin receptor type 2 internalization and recycling through Rab5 and Rab4 sorting endosomes in tumor somatotroph cells. *Neuroendocrinology*. (DOI: 10.1159/000503791). The final, published version is available at <http://www.karger.com/?doi=10.1159/000503791>.

## General rights

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

## Take down policy

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact [UBIRA@lists.bham.ac.uk](mailto:UBIRA@lists.bham.ac.uk) providing details and we will remove access to the work immediately and investigate.

Download date: 24. Apr. 2024

**Cytoskeleton protein Filamin A is required for efficient Somatostatin receptor type 2  
internalization and recycling through Rab5 and Rab4 sorting endosomes  
in tumor somatotroph cells.**

Donatella Treppiedi<sup>1</sup>, Federica Mangili<sup>1</sup>, Elena Giardino<sup>1</sup>, Rosa Catalano<sup>1,2</sup>, Marco Locatelli<sup>3</sup>, Andrea Lania<sup>4</sup>, Anna Spada<sup>1</sup>, Maura Arosio<sup>1</sup>, Davide Calebiro<sup>5,6,7</sup>, Giovanna Mantovani<sup>1</sup>, Erika Peverelli<sup>1</sup>.

<sup>1</sup> Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Endocrinology Unit; Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy.

<sup>2</sup> PhD Program in Endocrinological Sciences, Sapienza University of Rome, Rome, Italy.

<sup>3</sup> Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Neurosurgery Unit; Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy.

<sup>4</sup> Endocrine Unit, IRCCS Humanitas Clinical Institute, Humanitas University, Rozzano, Italy.

<sup>5</sup> Institute of Pharmacology and Toxicology and Bio-Imaging Center, University of Würzburg, Würzburg, Germany.

<sup>6</sup> Institute of Metabolism and Systems Research, University of Birmingham, Birmingham, United Kingdom.

<sup>7</sup> Centre of Membrane Proteins and Receptors, University of Birmingham, Birmingham, United Kingdom.

**\* Corresponding Author:**

Giovanna Mantovani

Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Endocrinology Unit; Department of Clinical Sciences and Community Health, University of Milan.

Via F. Sforza, 35

20122 Milan, Italy

Phone +39 02 55033481

E-mail: giovanna.mantovani@unimi.it

**Keywords:** SST<sub>2</sub>, FLNA, intracellular trafficking

**Running Title:** FLNA regulates SST<sub>2</sub> intracellular sorting

## **Abstract**

The high expression of somatostatin receptor 2 (SST<sub>2</sub>) in growth hormone (GH)-secreting tumors represents the rationale for the clinical use of somatostatin analogs (SSAs) in acromegaly. Recently, the cytoskeletal protein Filamin A (FLNA) has emerged as key modulator of the responsiveness of GH-secreting pituitary tumors to SSAs by regulating SST<sub>2</sub> signaling and expression.

The aim of this study was to explore FLNA involvement in SST<sub>2</sub> intracellular trafficking in tumor somatotroph cells.

By biotinylation assay we found that FLNA silencing abolished octreotide-mediated SST<sub>2</sub> internalization in rat GH3 cell line (28.0±2.7% vs 4±4.3% SST<sub>2</sub> internalization, control vs FLNA siRNA cells, respectively, P<0.001) and human GH-secreting primary cultured cells (70.3±21.1% vs 24±19.2% SST<sub>2</sub> internalization, control vs FLNA siRNA cells, respectively, P<0.05). In addition, confocal imaging revealed impaired SST<sub>2</sub> recycling to the plasma membrane in FLNA silenced GH3 cells.

Co-immunoprecipitation and immunofluorescence experiments showed that FLNA, as well as β-arrestin2, is timely-dependent recruited to octreotide-stimulated SST<sub>2</sub> receptors both in rat and human tumor somatotroph cells. Although FLNA expression knock down did not prevent the formation of β-arrestin2-SST<sub>2</sub> complex in GH3 cells, it significantly impaired efficient SST<sub>2</sub> loading into cytosolic vesicles positive for the early endocytic and recycling markers Rab5 and Rab4,

respectively ( $33.7\pm 8.9\%$  down to  $25.9\pm 6.9\%$ ,  $p<0.05$ , and  $28.4\pm 7.4\%$  down to  $17.6\pm 5.7\%$ ,  $p<0.01$ , for SST<sub>2</sub>-Rab5 and SST<sub>2</sub>-Rab4 colocalization, respectively, in control vs FLNA siRNA cells).

Altogether these data support an important role for FLNA in the mediation of octreotide-induced SST<sub>2</sub> trafficking in GH-secreting pituitary tumor cells through Rab5 and Rab4 sorting endosomes.

## **Introduction**

The G protein-coupled receptor (GPCR) somatostatin receptor type 2 (SST<sub>2</sub>) is the most widely distributed somatostatin receptor in human tissues and neuroendocrine tumors [1,2]. Due to its well-established inhibitory effects on hormone release and cell proliferation, and its high levels of expression in these tumors, SST<sub>2</sub> is considered the main molecular target for long-acting somatostatin analogs (SSAs) treatment in growth hormone (GH)-secreting pituitary tumors [3,4]. However, despite high expression of SST<sub>2</sub>, a consistent subset of patients harboring a GH-secreting pituitary tumor is not successfully controlled by the medical therapy, showing poor or lacking GH and IGF-1 normalization [5,6]. In the last decades, several studies have attempted to characterize new molecular factors responsible for this variability in the response to the SSAs octreotide and lanreotide [7,8].

Intracellular endosome trafficking has emerged as a critical aspect of GPCRs regulation, able to affect receptor cell surface availability and signaling, with consequences for the responsiveness to physiological ligands and drugs [9,10].

A pleiotropic role of the cytoskeleton protein filamin A (FLNA) in the intracellular trafficking of several membrane receptors has been demonstrated [11]. From a structural point of view, FLNA is a 280 kDa homodimeric protein composed of an N-terminal actin-binding domain and 24 Ig-like repeats of about 96 amino acids. FLNA stabilizes cortical three-dimensional actin filament networks and links them to cellular membranes. Furthermore, it acts as a scaffold platform for intracellular molecules involved in different signaling pathways [11,12]. Previous studies showed that FLNA integrates cell signaling events and cell shape changes that ultimately dictate pituitary tumors drug

responsiveness and invasiveness [13-15]. In particular, in tumor somatotroph cells, SST<sub>2</sub> directly binds FLNA and this interaction is essential for SST<sub>2</sub>-mediated antiproliferative effects and for SST<sub>2</sub> protein levels stability after prolonged agonist stimulation [14]. Moreover, in CHO cells transfected with human SST<sub>2</sub>, FLNA modulates receptor mobility at the plasma membrane and actively cooperates in ligand-induced SST<sub>2</sub> clusters formation, alignment on actin filaments and internalization [16].

As for most other GPCRs, agonist-stimulation promotes SST<sub>2</sub> endocytosis via causing its phosphorylation by G protein-coupled receptor kinases at serine and threonine residues located at its C-terminus, followed by  $\beta$ -arrestin recruitment [17-20]. In the context of acromegaly, controversial data are present in the literature regarding the correlation between  $\beta$ -arrestins and SST<sub>2</sub> expression and responsiveness of GH-secreting pituitary tumors to SSAs [21-23]. Although FLNA is a known  $\beta$ -arrestin binding partner in mammalian cells [24,25], a contribution of FLNA in the  $\beta$ -arrestin-recruitment of SST<sub>2</sub> has not been investigated yet. Once in the cytoplasm, SST<sub>2</sub> does not follow a degradation route, as no detectable lysosome or proteasome-mediated degradation of SST<sub>2</sub> has been observed in HEK293 or the rat GH-secreting pituitary cell line GH3. Indeed, only GH3 cells lacking FLNA- SST<sub>2</sub> interaction showed receptor downregulation after prolonged agonist stimulation [14,17,26].

Receptor sorting within endosome trafficking is regulated by members of the Rab family of small GTPases whose functions are membrane budding, docking, and interaction with the cytoskeleton [27,28]. Rab4, Rab21, and Rab11 have been identified as key regulators of SST<sub>3</sub> trafficking [29], however no detailed data are available in the literature about SST<sub>2</sub> dynamics inside the cell.

Since in many cases receptor trafficking is facilitated by actin filaments dynamics [30,31], here we tested a role of FLNA in the postendocytic sorting and recycling of SST<sub>2</sub> both in rat and human tumor somatotroph cells.

## **Materials and Methods**

### **Cell culture**

Rat tumoral pituitary GH3 cells (ATCC CCL-82.1) and GH4C1 cells (ATCC CCL-82.2) were cultured in F12K and F10 medium, respectively, supplemented with 15% Horse Serum (HS), 2.5% Fetal Bovine Serum (FBS), 2 mM glutamine and antibiotics. Human pituitary cells were obtained by the transphenoidal route from a total of 10 patients with GH-secreting tumors. Tissues were subjected to an enzymatic dissociation in DMEM containing 2 mg/mL collagenase at 37 °C for 2 h, as previously described [14]. Dispersed cells were grown in DMEM supplemented with 10% FBS, 2 mM glutamine, and antibiotics. The study was approved by the local ethics committee and informed consent was obtained from patients involved in the study.

### **Plasmids transfection and FLNA silencing**

Expression vectors coding for human HA-SST<sub>2</sub> (influenza hemagglutinin-tagged SST<sub>2</sub>), SNAP-SST<sub>2</sub> (SST<sub>2</sub> fused to SNAP tag, a 20-kDa protein derived from the enzyme *O*<sup>6</sup>-alkylguanine-DNA alkyltransferase), EGFP- $\beta$ -arrestin2 (enhanced green fluorescent protein-tagged  $\beta$ -arrestin2) and FLNA truncated mutants (FLNA 19-20, FLNA 21-24) were previously described [14,16,32]. These vectors were transiently transfected in GH3 and GH4C1 cells using Lipofectamine 2000 as reagent (Invitrogen, Carlsbad, CA) according to the manufacturer's instruction. Transfection efficiency was evaluated by fluorescence microscopy in each experiment. Only experiments with transfection efficiency > 60% were accepted. Corresponding empty vectors were used in each experiment as negative controls. FLNA gene silencing was performed in GH3 cells and GH-secreting tumor primary cells using rat or human FLNA predesigned small interfering RNAs (siRNAs), respectively, and Dharmafect transfection agent 2 (Dharmacon, GE Healthcare Life Sciences, Chicago, IL) according to the instruction of the manufacturer. A negative control (scramble) siRNA was used in each experiment. The optimal concentration of siRNAs and the kinetics of silencing of FLNA were established in preliminary experiments and 72 h of silencing was chosen as optimal time point. For

simultaneous plasmids transfections and FLNA gene silencing, cells were co-transfected for 72 h with vectors of interest and FLNA siRNAs using Lipofectamine 2000 as transfection agent following the manufacturer's instructions.

### **Biotinylation assay**

To perform quantitative analysis of SST<sub>2</sub> internalization, GH3 and GH4C1 cells were seeded at the cell density of  $1 \times 10^6$  cells in 10 cm petridish, transiently co-transfected with FLNA siRNA and HA-SST<sub>2</sub> the following day. GH-secreting tumor primary cells were plated at the cell density of  $5 \times 10^6$  cells in p6 multiwell plate and silenced for FLNA. Biotinylation of cell surface-receptors was assessed accordingly to the previously described protocol [16] and glutathione (Sigma-Aldrich, St. Louis, MO) was used to release the biotin label from proteins at the cell surface. SST<sub>2</sub> internalization was promoted by stimulation with 100 nM octreotide for 30 min. For immunoprecipitation, 200  $\mu$ g of total cellular protein extract was mixed with 1  $\mu$ g SST<sub>2</sub> (yI-17) antibody (Santa Cruz Biotechnology, Santa Cruz, CA) overnight on a rotating device at 4 °C. Twenty  $\mu$ l of protein G Plus-Agarose (Santa Cruz Biotechnology, Santa Cruz, CA) was added afterwards. Ice-cold PBS (Thermofisher, Rockfor, IL), was used to wash the pellet and 45  $\mu$ l of Blue loading buffer (Cell Signaling Technology, Danvers, MA) for resuspension. Eluted proteins were separated by SDS-PAGE under nonreducing conditions. Anti-FLNA antibody (1:1000, Abnova, Taiwan, RC) was used to test FLNA silencing efficiency and only experiments with silencing efficiency > 80% were considered. Biotinylated proteins were detected with a 1:500 diluted horseradish peroxidase-linked antibody specific for biotin (Cell Signaling Technology, Danvers, MA). The presence of equal SST<sub>2</sub> amounts in the immunoprecipitates was confirmed by stripping and reprobing with an antibody against SST<sub>2</sub> (1:1000; UMB-1, Abcam, Cambridge, UK) and using an anti-mouse secondary antibody covalently coupled to horseradish peroxidase (1:2000). The obtained bands were analyzed with the NIH ImageJ software. Experiments were performed in triplicate in rat cell lines and in primary cultures from 3 different GH-secreting pituitary tumors.

### **Co-immunoprecipitation of SST<sub>2</sub>-β-arrestin2-FLNA**

To test FLNA and β-arrestin2 recruitment to SST<sub>2</sub>, GH3 cells were seeded at the cell density of 3,3 x 10<sup>5</sup> cells in p6 multiwell plate for 18 h at 37 °C, then simultaneously silenced for FLNA and transiently co-transfected with EGFP-β-arrestin2 and HA-SST<sub>2</sub>. Cells were incubated in presence or absence of octreotide (100 nM) at 37 °C for the indicated times (2, 5, 10, 30 min) and then lysed. The homogenates were centrifuged and 150 μg of supernatant incubated with 1 μg of SST<sub>2</sub> (yI-17) antibody, followed by 20 μl volume of Protein G PLUS-Agarose beads addition, as above described. After final wash, the pellet was resuspended in 45 μl of Blue loading buffer containing reducing agents and analyzed by Western blot. FLNA and EGFP-β-arrestin2 were detected by anti-FLNA (1:1000, Abnova, Taiwan, RC) and anti-GFP primary antibodies (Clontech, CA, USA, diluted 1:1000), respectively, and anti-mouse and anti-rabbit secondary antibodies (diluted 1:2000), respectively. Experiments were repeated three times.

### **Immunofluorescence**

GH3 and human GH-secreting pituitary cultured cells were plated on 13-mm poly-L-lysine coated coverslips at a density of 125 × 10<sup>3</sup> cells/well in 24-well plates and grown at 37 °C for 18 h, and subjected to transient transfection or gene silencing the following day. In GH3 cells SNAP-SST<sub>2</sub> receptors were labeled with AlexaFluor™ 647-BG (ThermoFisher Scientific, CA) 1 μM for 20 min at 37 °C, as previously described [16]. Cells were incubated with octreotide 100 nM at 37°C for 5, 15 or 30 min for β-arrestin2 mobilization, SST<sub>2</sub>-Rab4/5 colocalization, and SST<sub>2</sub> internalization analysis, respectively. For wash out experiments cells were stimulated for 30 min at 37 °C with 100 nM octreotide, then extensively washed with warm medium and finally let at 37° for 30 min in fresh medium. Cells were fixed for 10 min at room temperature with 4% paraformaldehyde (Sigma-Aldrich, St. Louis, MO), followed by three washes with PBS and incubated 1 h at room temperature with blocking buffer (5% FBS, 0.3% Triton™X-100, in PBS). The overnight incubation with anti-



FLNA (1:200, Abnova, Taiwan, RC) and anti-Rab4 (1:200, ThermoFisher Scientific, CA) or anti-Rab5 (1:200, Cell Signaling Technology, Danvers, MA) antibodies was performed at 4 °C. The anti-SST<sub>2</sub> antibody was used to stain SST<sub>2</sub> receptor in human primary cultured cells (UMB1, Abcam, Cambridge, UK, 1:100). After that, anti-mouse Alexa Fluor™ -546-conjugated secondary antibody (1:500, ThermoFisher Scientific, CA), or anti-rabbit Alexa Fluor™ -488-conjugated secondary antibody (1:1000, ThermoFisher Scientific, CA), and anti-rabbit Alexa Fluor™ -647-conjugated secondary antibody (1:1000, ThermoFisher Scientific, CA) was incubated at room temperature for 1 h. All antibodies were diluted in Antibody Diluent Reagent Solution (Life Technologies, ThermoFisher, CA). Coverslips were mounted on glass slides with ProLong Diamond Antifade mounting medium with 4',6-diamidino-2-phenylindole (DAPI) (Life Technologies, Carlsbad, CA) for subsequent observation.

### **Confocal fluorescence microscopy and colocalization analysis**

Images of representative intracellular optical section were acquired at Leica TCS SP2 laser scanning confocal microscope equipped with Ar 488 nm, HeNe 543 nm and 635 nm lines and a 63× objective (HCX PL APO 63X/1.4-0.60 OIL) (Leica Microsystems, Wetzlar, Germany). Acquisition was conducted at 1240 × 1240 pixels. Images were obtained using sequential scanning for each channel in order to avoid possible “cross-talk” of chromophores and photomultiplier gain adjusted to limit background noise and avoid saturated pixels. After background correction, RGB profile intensity and Manders’ correlation coefficient (MCC) was used to measure the degree of colocalization between SST<sub>2</sub> and Rab5 or Rab4 with the JACoP tool in the NIH ImageJ software.

### **Statistical Analysis**

All statistical analyses were performed using the Prism 7 software (GraphPad, San Diego, CA). Data were analyzed by two-tailed paired Student *t* test. The results are expressed as the mean ± SD and *P* < 0.05 was accepted as statistically significant.

## Results

### 1. Efficient octreotide-induced SST<sub>2</sub> internalization requires FLNA

Recent experiments published by our group had demonstrated that the interaction of FLNA with SST<sub>2</sub> is essential for SST<sub>2</sub> recruitment to clathrin coated pits and subsequent internalization in CHO cells treated with the SST<sub>2</sub> selective ligand, BIM23120 [16]. Here, we tested whether FLNA was involved in SST<sub>2</sub> endocytosis in tumor somatotroph cells. By siRNA techniques we knocked down FLNA expression in rat GH-secreting pituitary tumor GH3 cells which we stimulated for 30 min to induce SST<sub>2</sub> internalization. Biotinylation experiments showed a statistically significant decrease of octreotide-induced SST<sub>2</sub> internalization in FLNA siRNA transfected cells compared with control cells (28.0±2.7% vs 4±4.3% SST<sub>2</sub> internalization, control vs FLNA SiRNA cells, respectively, P<0.001) (Fig.1A). In agreement, comparable data were obtained in rat GH4C1 cells (data not shown). Moreover, similar results were observed in human GH-secreting pituitary tumor cultured cells from 5 patients, where FLNA silencing impaired SST<sub>2</sub> internalization upon octreotide stimulation (70.3±21.1% vs 24±19.2% SST<sub>2</sub> internalization, control vs FLNA SiRNA cells, respectively, P<0.05) (Fig.1B).

### 2. FLNA is required for SST<sub>2</sub> recycling to the plasma membrane

Receptor recycling back to the plasma membrane represents a crucial aspect of receptor resensitization. To evaluate SST<sub>2</sub> recycling, we performed immunofluorescence experiments both in GH-secreting pituitary primary cultured cells and GH3 cells. 30-min cells exposure to octreotide firstly induced SST<sub>2</sub> to translocate from cell surface into the cytoplasm. Subsequently, 30 min of octreotide removal allowed internalized SST<sub>2</sub> receptor pool to almost completely recycle back to the plasma membrane (Fig. 2A&B). We then asked whether FLNA is required for receptor recycling. To address this question, GH3 cells were silenced for FLNA and simultaneously transfected with SNAP-SST<sub>2</sub> and then treated as above described. In agreement to that observed in human tumor somatotroph

cells, cell surface recycling of SST<sub>2</sub> was detected during wash-out experiments in control cells. On the contrary, 30-min octreotide incubation only partially induced SST<sub>2</sub> internalization in FLNA-silenced cells. Moreover, under this condition of FLNA depletion the internalized SST<sub>2</sub> pool remained sequestered into intracellular compartment after the wash/out step, demonstrating that, without FLNA, SST<sub>2</sub> fails to reach to the plasma membrane (Fig. 2B).

### **3. FLNA and $\beta$ -arrestin2 are recruited to cell surface activated SST<sub>2</sub>**

FLNA has been shown to directly bind  $\beta$ -arrestins through its C-terminal repeat 22 [25]. The GH3 cell line expresses both  $\beta$ -arrestin1 and  $\beta$ -arrestin2 mRNA [21]. However, in contrast to  $\beta$ -arrestin2,  $\beta$ -arrestin1 is almost undetectable by western blot analysis (data not shown). Therefore, we investigated the recruitment kinetics of FLNA and  $\beta$ -arrestin2 to cell-surface SST<sub>2</sub>. As shown in figure 3A, under basal conditions SST<sub>2</sub> was exclusively located at the plasma membrane where it partially colocalized with FLNA, whereas  $\beta$ -arrestin2 was widely distributed in the cytoplasm. A 2-min octreotide exposure triggered a rapid  $\beta$ -arrestin2 recruitment to the cell surface where it colocalized with SST<sub>2</sub> and FLNA. As expected, after 5-10 min of octreotide stimulation,  $\beta$ -arrestin2 and SST<sub>2</sub> appear together as internalizing punctate clusters and almost complete endocytosis of SST<sub>2</sub>- $\beta$ -arrestin-2 complexes was induced by prolonged agonist stimulation (30 min). Interestingly, FLNA translocation from the plasma membrane to the cytosol was visualized after 30 min. To confirm these observations we used a biochemical approach. Representative western blot images of co-immunoprecipitation experiments reported in figure 3B show that FLNA and  $\beta$ -arrestin2 interact with SST<sub>2</sub> to form a complex, and that octreotide-induced FLNA and  $\beta$ -arrestin2 binding to SST<sub>2</sub> is maximal at 2 min.

Furthermore, a similar redistribution of FLNA and  $\beta$ -arrestin2 signals was observed in human primary cells obtained from GH-secreting pituitary tumors and treated with octreotide (Fig. 3C).

### **4. $\beta$ -arrestin2 binding to SST<sub>2</sub> is FLNA-independent**

As efficient SST<sub>2</sub> internalization requires FLNA, we investigated whether FLNA could play a role in facilitating or stabilizing  $\beta$ -arrestin2 association with SST<sub>2</sub>, being this a critical step of ligand-induced GPCR endocytosis. To this aim, we silenced FLNA expression in GH3 cells and stimulated cells for 0, 5 or 30 min with octreotide. As shown by confocal images, 5 min after SST<sub>2</sub> activation,  $\beta$ -arrestin2 translocated from the cytoplasm to the plasma membrane both in control and FLNA-deficient cells, and SST<sub>2</sub>- $\beta$ -arrestin2 complexes colocalized regardless of FLNA expression (Fig. 4A). Accordingly, co-immunoprecipitation results demonstrated that SST<sub>2</sub>- $\beta$ -arrestin2 interaction upon receptor activation occurs either in the presence or absence of FLNA (Fig. 4B), suggesting that FLNA is not essential for the formation of SST<sub>2</sub>- $\beta$ -arrestin2 complex. The occurrence of FLNA-independent  $\beta$ -arrestin2 recruitment to SST<sub>2</sub> was further confirmed by using dominant negative FLNA mutants FLNA 19-20 and FLNA 21-24 [14] that selectively interfere with the ability of endogenous FLNA to bind SST<sub>2</sub> and  $\beta$ -arrestin-2, respectively (Suppl.Fig.1).

#### **5. SST<sub>2</sub> intracellular endosomal sorting is regulated by FLNA.**

Next, we tested whether FLNA might be directly involved in the intracellular route followed by SST<sub>2</sub> once endocytosed. To this purpose, we analyzed the extent of SST<sub>2</sub> colocalization with Rab5 and Rab4, two well-defined endosomal markers of early endosomes and a fast recycling compartment, respectively, in GH3 cells treated with octreotide for 15 min. Interestingly, Manders' coefficient analysis performed on confocal images revealed that the fraction of SST<sub>2</sub> colocalizing with Rab5 and Rab4-positive endosomes observed in control cells was significantly reduced in the absence of FLNA ( $33.7 \pm 8.9\%$  down to  $25.9 \pm 6.9\%$  and  $28.4 \pm 7.4\%$  down to  $17.6 \pm 5.7\%$ , MCC for SST<sub>2</sub>-Rab5 and SST<sub>2</sub>-Rab4 colocalization in control vs FLNA silenced cells, respectively) (Fig. 2A&B).

These results suggest that FLNA might contribute to the regulation of SST<sub>2</sub> trafficking to early endosomes and the Rab4 recycling compartment.

## **Discussion**

With the present study we describe a crucial role of the cytoskeleton protein FLNA in SST<sub>2</sub> internalization and trafficking along the endocytic pathway both in human and rat tumor GH-secreting pituitary cells.

As far as GPCRs expressed in pituitary cells are concerned, SST<sub>2</sub> represents the main molecular target for the medical therapy with SSA of GH-secreting tumors in acromegalic patients. Previous data obtained by our group showed that FLNA is a key modulator of SST<sub>2</sub> stabilization and signaling in tumor somatotroph cells [14,33], and that transient SST<sub>2</sub>-FLNA interactions occur in living CHO cells to preferentially localize receptors along actin fibers, allowing efficient ligand-promoted SST<sub>2</sub> recruitment to clathrin-coated pits and internalization [15].

Here, we firstly demonstrate that FLNA is required for correct octreotide-induced SST<sub>2</sub> internalization in rat GH-secreting pituitary tumor GH3 cells. Accordingly, SST<sub>2</sub> internalization was affected by FLNA knock down in primary cultures from 5 dispersed GH-secreting pituitary tumors. In this regard, the structural and functional properties of FLNA have been extensively investigated and found implicated in the internalization process of a variety of transmembrane receptors, such as dopamine receptor type 2 and 3 (DRD2 and DRD3) [34-36], mu opioid receptor [37], furin receptor [38] and chemotactic cytokine receptor 2B (CCR2B) [39], in different cell types. Moreover, we show that SST<sub>2</sub> receptors almost completely reach the plasma membrane after washout of octreotide both in rat and human tumor GH-secreting pituitary cells. Similar results have been obtained by previous studies in HEK293 cells and hippocampal neurons [17,40,41]. Importantly, our data in GH3 cells demonstrate that FLNA is required to sustain efficient SST<sub>2</sub> recycling. Indeed, the absence of FLNA resulted in SST<sub>2</sub> accumulation in the perinuclear region of the cell and a failure in reaching the plasma membrane during washout experiments. This finding likely indicates that SST<sub>2</sub> is redirected to lysosomes for degradation, in accordance with our previous results of an increased lysosome-mediated SST<sub>2</sub> downregulation observed after prolonged agonist exposure in GH3 cells lacking SST<sub>2</sub>-FLNA binding [14]. It is worth noting that, under resting condition, FLNA depletion does not affect SST<sub>2</sub> correct localization at the plasma membrane in somatotroph cells, this being in line with the

literature [14]. Such observation allowed to establish an initial setpoint that would not compromise the analysis of receptor internalization and recycling of FLNA silenced cells.

In an attempt to unveil the molecular mechanisms governing FLNA effects on SST<sub>2</sub> internalization and recycling, here we excluded the involvement of FLNA in the recruitment of the predominant  $\beta$ -arrestin isoform expressed in GH-secreting pituitary tumors and GH3 cells [21],  $\beta$ -arrestin2, to ligand-activated SST<sub>2</sub>. Our imaging and co-immunoprecipitation data show that both FLNA and  $\beta$ -arrestin2 are immediately recruited to octreotide-activated SST<sub>2</sub> at the cell surface (2 min after SST<sub>2</sub> stimulation), this being followed by their interaction with SST<sub>2</sub> clusters (5-10 min after SST<sub>2</sub> stimulation), subsequent  $\beta$ -arrestin2-SST<sub>2</sub> internalization and FLNA redistribution to the cytoplasm (30 min after SST<sub>2</sub> stimulation). However,  $\beta$ -arrestin2 still retains the capacity to bind SST<sub>2</sub> in the absence of FLNA in GH3 cells. Similarly, the lack of FLNA did not prevent  $\beta$ -arrestin2 recruitment to DRD3 in M2 cells [24]. The biological implication of such  $\beta$ -arrestin2-SST<sub>2</sub> complexes, regardless FLNA expression, still deserves further investigations.

Moreover, our immunofluorescence experiments show that 15 min of cells exposure to octreotide promotes SST<sub>2</sub> accumulation at both Rab5-positive early endosomes and Rab4-positive recycling compartment, suggesting that SST<sub>2</sub> might undergo rapid recycling. Typically, fast recycling of receptors to the plasma membrane promotes functional resensitization. To the best of our knowledge, this is the first evidence showing the intracellular routes followed by human SST<sub>2</sub> in tumor somatotroph cells. Upon stimulation, rat *sst2A* has been shown to accumulate at intracellular vesicles containing endocytosed transferrin, a well-characterized marker of fast recycling, both in transfected HEK293 cells and hippocampal neurons [17,41]. Interestingly, in FLNA silenced GH3 cells, octreotide treatment fails to properly induce SST<sub>2</sub> localization at such endosomal domains. This finding suggests that FLNA might play a crucial cargo adaptor function to sustain efficient SST<sub>2</sub> internalization and trafficking through the endosomal compartments. Moreover, it indicates a different mechanism underlying the impairment of SST<sub>2</sub> endocytosis in FLNA depleted cells beside  $\beta$ -arrestin2 mobilization to activated SST<sub>2</sub>.

A pleiotropic role of FLNA in regulating endosomal trafficking emerged from recent high-speed imaging experiments performed by Pons and colleagues [42]. Their data showed a decreased endosomal motility and shorter distance travelled within the cytoplasm of chemokine receptor CCR2 (CCR2B)-loaded endosomes in FLNA silenced HEK293 cells compared to control cells. Since by single-molecule microscopy we were able to demonstrate that SST<sub>2</sub> interactions with FLNA are increased by agonist stimulation and play a role in confining SST<sub>2</sub> diffusion on the plasma membrane [16], it is possible to speculate that FLNA might regulate the dynamic behavior of ligand activated-SST<sub>2</sub> endosomal trafficking, accordingly. Thus, further experiments are needed to verify this hypothesis.

In conclusion, the present work highlights the importance of FLNA for efficient octreotide-mediated SST<sub>2</sub> intracellular trafficking in tumor GH-secreting pituitary cells. At the same time, it shows that FLNA sustains proper endocytic machinery that ultimately influences the number of available SST<sub>2</sub> at the cell surface. Further studies are required to uncover the finely regulated molecular mechanisms governing the modulation of SST<sub>2</sub>-FLNA interactions. Indeed, they might provide insights for the development of innovative therapeutic strategy for patients with GH-secreting pituitary tumors unresponsive to SSA.

## Figure Legends

**Figure 1. FLNA silencing affects octreotide-mediated SST<sub>2</sub> internalization.** Biochemical analysis of SST<sub>2</sub> internalization based on biotinylation of membrane receptors in rat (A) and human GH-secreting pituitary tumor cells (B). At 72 h after siRNA transfection (and simultaneous co-transfection with wild-type SST<sub>2</sub> for GH3 cells, only), cells were incubated with or without 100 nM octreotide for 30 min. Total proteins were immunoprecipitated by SST<sub>2</sub> specific antibody, and the internalized/biotinylated SST<sub>2</sub> was detected with an antibody recognizing biotin. The assay shows reduced SST<sub>2</sub> internalization in stimulated FLNA silenced cells compared to negative control cells both in rat and human tumor somatotroph cells. Shown are the mean  $\pm$  SD of three independent

experiments in GH3 cells and five independent experiments in distinct GH-secreting primary cultures. \*\*\*,  $P < 0.001$ , \*,  $P < 0.05$  vs negative control cells; §§§,  $P < 0.001$ , §,  $P < 0.05$  vs. corresponding basal condition by unpaired Student's t test.

**Figure 2. FLNA sustains SST<sub>2</sub> recycling to the plasma membrane.** (A) Human GH-secreting pituitary tumor cells were exposed for 30 min to 100 nM octreotide, extensively washed and incubated with an agonist-free medium for further 30 min. Cells were subsequently fixed and immunostained for endogenous SST<sub>2</sub> (magenta) and FLNA (green). Experiments were repeated in two different human primary cultures. (B) Rat GH3 cells were simultaneously transfected with plasmid encoding SNAP-SST<sub>2</sub> and siRNA for FLNA (right panel) or negative control (middle panel). After 72 h receptors were labelled (magenta) and cells were treated as above described, fixed and immunostained for FLNA (green). Shown are representative confocal images acquired at the level of the nucleus stained with DAPI (blue). Arrows indicate major SST<sub>2</sub> cell localization (plasma membrane or intracellular compartment) for each conditions. For each condition, at least 10 cells from three independent experiments were analyzed. Scale bar, 10  $\mu\text{m}$ .

**Figure 3. Time course kinetics of the recruitment of FLNA and  $\beta$ -arrestin2 to octreotide-activated SST<sub>2</sub>.** (A) GH3 cells were transiently co-transfected with  $\beta$ -arrestin2 (green) and SNAP-SST<sub>2</sub> (magenta) for 48 h. Then receptor were labelled with Alexa-Fluor 647 dye and cells fixed prior or after stimulation with octreotide 100 nM for the indicate times. Immunostaining of endogenous FLNA (red) was performed. DAPI was used to stain the nuclei (blue). The panel show representative confocal images acquired for each channel separately and the overlay, from one of at least three independent experiments. Arrows indicate translocation of both FLNA and  $\beta$ -arrestin2 to the plasma membrane and their colocalization with SST<sub>2</sub> at the cell surface, at the compartment below the plasma membrane and at the inner cytosolic compartment, at 2 min, at 5 and 10 min and at 30 min after receptor stimulation, respectively. (B) Representative co-immunoprecipitation experiments showing



the kinetics of FLNA and  $\beta$ -arrestin2 binding to SST<sub>2</sub> performed in GH3 cells treated as above described. Lysates were immunoprecipitated (IP) with specific SST<sub>2</sub> antibody, and the presence of  $\beta$ -arrestin2, FLNA and SST<sub>2</sub> was detected using anti-GFP, anti-FLNA and anti-SST<sub>2</sub> antibodies, respectively. Experiments were repeated three times and densitometrical analysis of Western blot images is shown. \*, P<0.05, vs. corresponding basal condition by unpaired Student's t test. (C) Representative confocal images of human GH-secreting pituitary cells transiently transfected with  $\beta$ -arrestin2 (green) exposed to octreotide for 0, 2 and 30 min, fixed and immunostained for endogenous FLNA (red). Shown are the single channels and the overlay. Arrows indicate yellow region of the cell where FLNA and  $\beta$ -arrestin2 colocalize. Experiments were repeated in three different human primary cultures.

**Figure 4. Effects of FLNA silencing on  $\beta$ -arrestin2 mobilization to cell surface SST<sub>2</sub>.** (A) GH3 cells were simultaneously transfected with  $\beta$ -arrestin2 (green), SNAP- SST<sub>2</sub> (magenta) and negative control (upper panels) or FLNA siRNA (lower panels). After 72 h, SNAP-SST<sub>2</sub> were labelled with Alexa-Fluor 647 dye, and cells were stimulated or not with octreotide 100 nM for 5 min and fixed. Endogenous FLNA (red) was immunostained with specific antibody and DAPI was used to stain the nuclei (blue). Shown are representative confocal images acquired at the level of the nucleus from one of at least three independent experiments. Arrows indicate translocation of  $\beta$ -arrestin2 to the plasma membrane where it colocalizes with SST<sub>2</sub>. Scale bar, 10  $\mu$ m. (B) Representative co-immunoprecipitation experiment performed in GH3 cells simultaneously transfected with  $\beta$ -arrestin2, HA-SST<sub>2</sub> and negative control or FLNA siRNA for 72 h and stimulated with octreotide 100 nM for the indicated times. Total protein extracts were immunoprecipitated (IP) with an antibody recognizing SST<sub>2</sub>, and the presence of  $\beta$ -arrestin2, FLNA and SST<sub>2</sub> was assessed by western blot analysis with anti-GFP, anti-FLNA and anti-SST<sub>2</sub> specific antibodies, respectively. Experiments were repeated three times.

### **Figure 5. FLNA facilitates SST<sub>2</sub> loading in Rab5 and Rab4-positive endosomes.**

Colocalization analysis of SST<sub>2</sub>-Rab5 (A) and SST<sub>2</sub>-Rab4 (B) in GH3 cells simultaneously transfected with SNAP-SST<sub>2</sub> and negative control or FLNA siRNA. After 72 h, SNAP-SST<sub>2</sub> were labelled with Alexa-Fluor 647 dye and cells were exposed to octreotide 100 nM for 15 min. Cells were fixed with 4% PFA and immunostaining of FLNA (red), Rab5 (green) and Rab4 (green) was performed. Left, representative negative control and FLNA siRNA transfected cells from one of three independent experiments and expanded views of the regions marked with the yellow boxes showing individual endosomes and SST<sub>2</sub>. Scale bar, 10 μm. Middle, representative fluorescence intensity profiles of SST<sub>2</sub> (red) together with Rab5 or Rab4 (green) from corresponding selected areas marked with the yellow boxes and analyzed with the tool “RGB profile” in the NIH ImageJ software. Right, graphs showing the quantification of SST<sub>2</sub> colocalization with Rab5 or Rab4 in control and FLNA silenced cells, according to Menders’ colocalization coefficient (MCC). Results are expressed as mean ± SD \*, P<0.05, \*\*, P<0.01 vs. negative control cells by unpaired Student’s t test.

### **Statement of Ethics**

The study was approved by the local ethics committees.

### **Disclosure Statement**

The authors declare that there are no conflicts of interest that could be perceived as prejudicing the impartiality of the research reported.

### **Funding Sources**

This work was supported by AIRC (Associazione Italiana Ricerca Cancro) grant to G.M. [IG 2017-20594], Pfizer grant to E.P. [WI219094], Ricerca Corrente Funds from the Italian Ministry of Health, Progetti di Ricerca di Interesse Nazionale (PRIN) grant to G.M. [2015ZHKFTA] and grant to G.M. Ricerca Finalizzata PE-2016-02361797.

## **Author Contribution**

D.T. designed, performed, analyzed the experiments and wrote the manuscript; F.M., E.G., and R.C. contributed to the experiments; M.L. and A.L. provided tumor samples; A.S. provided intellectual input and critically reviewed the manuscript; M.A. provided intellectual input; D.C. critically reviewed the manuscript; G.M. and E.P. supervised the project, provided intellectual input and critically reviewed the manuscript.

## **Reference**

1. Günther T, Tulipano G, Dournaud P, Bousquet C, Csaba Z1, Kreienkamp HJ, et al. International union of basic and clinical pharmacology. cv. somatostatin receptors: structure, function, ligands, and new nomenclature. *Pharmacol Rev.* 2018 Oct;70(4):763-835.
2. Körner M, Eltschinger V, Waser B, Schonbrunn A, Reubi JC. Value of immunohistochemistry for somatostatin receptor subtype sst2A in cancer tissues: lessons from the comparison of anti-sst2A antibodies with somatostatin receptor autoradiography. *Am J Surg Pathol.* 2005 Dec;29(12):1642-51.
3. Gadelha MR, Kasuki L, Korbonits M. Novel pathway for somatostatin analogs in patients with acromegaly. *Trends Endocrinol Metab.* 2013 May;24(5):238–46.
4. Gadelha MR, Wildemberg LE, Bronstein MD, Gatto F, Ferone D. Somatostatin receptor ligands in the treatment of acromegaly. *Pituitary.* 2017 Feb;20(1)100-108.
5. Gatto F, Feelders RA, van der Pas R, Kros JM, Waaijers M, Sprij-Mooij D, et al. Immunoreactivity score using an anti-sst2A receptor monoclonal antibody strongly predicts the biochemical response

to adjuvant treatment with somatostatin analogs in acromegaly. *J Clin Endocrinol Metab.* 2013 Jan;98(1):E66–71.

6. Wildemberg LE, Neto LV, Costa DF, Nasciuti LE, Takiya CM, Alves LM, et al. Low somatostatin receptor subtype 2, but not dopamine receptor subtype 2 expression predicts the lack of biochemical response of somatotropinomas to treatment with somatostatin analogs. *J Endocrinol Invest.* 2013 Jan;36(1):38–43.

7. Colao A, Auriemma RS, Lombardi G, Pivonello R. Resistance to somatostatin analogs in acromegaly. *Endocr Rev.* 2011 Apr;32(2):247-71.

8. Peverelli E, Treppiedi D, Giardino E, Vitali E, Lania AG, Mantovani G. Dopamine and somatostatin analogues resistance of pituitary tumors: focus on cytoskeleton involvement. *Front Endocrinol (Lausanne).* 2015 Dec;6:187.

9. Irannejad R, Tomshine JC, Tomshine JR, Chevalier M, Mahoney JP, Steyaert J, et al. Conformational biosensors reveal GPCR signalling from endosomes. *Nature.* 2013 Mar; 495(7442):534-8.

10. Godbole A, Lyga S, Lohse MJ, Calebiro D. Internalized TSH receptors en route to the TGN induce local Gs-protein signaling and gene transcription. *Nat Commun.* 2017 Sep;8(1):443.

11. Nakamura F, Stossel TP, Hartwig JH. The filamins: organizers of cell structure and function. *Cell Adh Migr.* 2011 Mar;5(2):160-9.

12. Stossel TP, Condeelis J, Cooley L, Hartwig JH, Noegel A, Schleicher M, et al. Filamins as integrators of cell mechanics and signalling. *Nat Rev Mol Cell Biol.* 2001 Feb;2(2):138-45.
13. Peverelli E, Mantovani G, Vitali E, Elli FM, Olgiati L, Ferrero S, et al. Filamin-A is essential for dopamine D2 receptor expression and signaling in tumorous lactotrophs. *J Clin Endocrinol Metab.* 2012 Mar;97(3):967– 77.
14. Peverelli E, Giardino E, Treppiedi D, Vitali E, Cambiagli V, Locatelli M, et al. Filamin A (FLNA) plays an essential role in somatostatin receptor 2 (SST2) signaling and stabilization after agonist stimulation in human and rat somatotroph tumor cells. *Endocrinology.* 2014 Aug;155(8):2932– 41.
15. Coelho MCA, Vasquez ML, Wildemberg LE, Vázquez-Borrego MC, Bitana L, Camacho AHDS, et al. Clinical significance of filamin A in patients with acromegaly and its association with somatostatin and dopamine receptor profiles. *Sci Rep.* 2019 Feb;9(1):1122.
16. Treppiedi D, Jobin ML, Peverelli E, Giardino E, Sungkaworn T, Zabel U, et al. Single-molecule microscopy reveals dynamic flna interactions governing str2 clustering and internalization. *Endocrinology.* 2018 Aug;159(8):2953-65.
17. Tulipano G, Stumm R, Pfeiffer M, Kreienkamp HJ, Höllt V, Schulz S. Differential beta-arrestin trafficking and endosomal sorting of somatostatin receptor subtypes. *J Biol Chem.* 2004 May;279(20):21374-82.
18. Pöll F, Lehmann D, Illing S, Ginj M, Jacobs S, Lupp A, et al. Pasireotide and octreotide stimulate distinct patterns of sst2A somatostatin receptor phosphorylation. *Mol Endocrinol.* 2010 Feb;24(2):436-46.

19. Kao YJ, Ghosh M, Schonbrunn A. Ligand-dependent mechanisms of sst2A receptor trafficking: role of site-specific phosphorylation and receptor activation in the actions of biased somatostatin agonists. *Mol Endocrinol*. 2011 Jun;25(6):1040-54.
20. Lehmann A, Kliewer A, Schütz D, Nagel F, Stumm R, Schulz S. Carboxyl-terminal multi-site phosphorylation regulates internalization and desensitization of the human sst2 somatostatin receptor. *Mol Cell Endocrinol*. 2014 Apr;387(1-2):44-51.
21. Gatto F, Feelders R, van der Pas R, Kros JM, Dogan F, van Koetsveld PM, et al.  $\beta$ -Arrestin 1 and 2 and G protein-coupled receptor kinase 2 expression in pituitary adenomas: role in the regulation of response to somatostatin analogue treatment in patients with acromegaly. *Endocrinology*. 2013 Dec;154(12):4715-25.
22. Gatto F, Biermasz NR, Feelders RA, Kros JM, Dogan F, Van der Lely AJ, et al. Low beta-arrestin expression correlates with the responsiveness to long-term somatostatin analog treatment in acromegaly. *Eur J Endocrinol*. 2016 May;174(5):651-62.
23. Coelho MCA, Vasquez ML, Wildemberg LE, Vázquez-Borrego MC, Bitana L, Camacho AHDS, et al. Molecular evidence and clinical importance of  $\beta$ -arrestins expression in patients with acromegaly. *J Cell Mol Med*. 2018 Apr;22(4):2110-2116.
24. Kim KM, Gainetdinov RR, Laporte SA, Caron MG, Barak LS. G protein-coupled receptor kinase regulates dopamine D3 receptor signaling by modulating the stability of a receptor-filamin-beta-arrestin complex. A case of autoreceptor regulation. *J Biol Chem*. 2005 Apr;280(13):12774-80.

25. Scott MG, Pierotti V, Storez H, Lindberg E, Thuret A, Muntaner O, et al. Cooperative regulation of extracellular signal-regulated kinase activation and cell shape change by filamin A and beta-arrestins. *Mol Cell Biol.* 2006 May;26(9):3432-45.
26. Lesche S, Lehmann D, Nagel F, Schmid HA, Schulz S. Differential effects of octreotide and pasireotide on somatostatin receptor internalization and trafficking in vitro. *J Clin Endocrinol Metab.* 2009 Feb;94(2):654-61.
27. Hutagalung AH, Novick PJ. Role of Rab GTPases in membrane traffic and cell physiology. *Physiol Rev.* 2011 Jan;91(1):119-49.
28. Kjos I, Vestre K, Guadagno NA, Borg Distefano M, Progida C. Rab and Arf proteins at the crossroad between membrane transport and cytoskeleton dynamics. *Biochim Biophys Acta Mol Cell Res.* 2018 Jul;1865(10):1397-1409.
29. Tower-Gilchrist C, Lee E, Sztul E. Endosomal trafficking of the G protein-coupled receptor somatostatin receptor 3. *Biochem Biophys Res Commun.* 2011 Oct;413(4):555-60.
30. Derivery E, Sousa C, Gautier JJ, Lombard B, Loew D, Gautreau A. The Arp2/3 activator WASH controls the fission of endosomes through a large multiprotein complex. *Dev Cell.* 2009 Nov;17(5):712-23.
31. Gomez TS, Billadeau DD. A FAM21-containing WASH complex regulates retromer-dependent sorting. *Dev Cell.* 2009 Nov;17(5):699-711.

32. Cambiaghi V, Vitali E, Morone D, Peverelli E, Spada A, Mantovani G, et al. Identification of human Somatostatin Receptor 2 (SST2) domains involved in internalization and signaling in QGP-1 pancreatic neuroendocrine tumor cell line. *Endocrine*. 2017 Apr;56(1):146-157.
33. Peverelli E, Giardino E, Treppiedi D, Catalano R, Mangili F, Locatelli M, et al. A novel pathway activated by somatostatin receptor type 2 (SST2): Inhibition of pituitary tumor cell migration and invasion through cytoskeleton protein recruitment. *Int J Cancer*. 2018 May;142(9):1842-52.
34. Lin R, Karpa K, Kabbani N, Goldman-Rakic P, Levenson R. Dopamine D2 and D3 receptors are linked to the actin cytoskeleton via interaction with filamin A. *Proc Natl Acad Sci U S A*. 2001 Apr;98(9):5258-63.
35. Lin R, Canfield V, Levenson R. Dominant negative mutants of filamin A block cell surface expression of the D2 dopamine receptor. *Pharmacology*. 2002 Dec;66(4):173-81.
36. Cho EY, Cho DI, Park JH, Kurose H, Caron MG, Kim KM. Roles of protein kinase C and actin-binding protein 280 in the regulation of intracellular trafficking of dopamine D3 receptor. *Mol Endocrinol*. 2007 Sep;21(9):2242-54.
37. Onoprishvili I, Andria ML, Kramer HK, Ancevska-Taneva N, Hiller JM, Simon EJ. Interaction between the mu opioid receptor and filamin A is involved in receptor regulation and trafficking. *Mol Pharmacol*. 2003 Nov;64(5):1092-100.
38. Liu G, Thomas L, Warren RA, Enns CA, Cunningham CC, Hartwig JH, et al. Cytoskeletal protein ABP-280 directs the intracellular trafficking of furin and modulates proprotein processing in the endocytic pathway. *J Cell Biol*. 1997 Dec;139(7):1719-33.



39. Minsaas L, Planagumà J, Madziva M, Krakstad BF, Masià-Balagué M, Katz AA, et al. Filamin a binds to CCR2B and regulates its internalization. *PLoS One*. 2010 Aug;5(8):e12212 .
40. Csaba Z, Lelouvier B, Viollet C, E Ghouzzi V, Toyama K, Videau C, et al. Activated somatostatin type 2 receptors traffic in vivo in central neurons from dendrites to the trans Golgi before recycling. *Traffic*. 2007 Jul;8(7):820-34.
41. Lelouvier B, Tamagno G, Kaindl AM, Roland A, Lelievre V, Le Verche V, et al. Dynamics of somatostatin type 2A receptor cargoes in living hippocampal neurons. *J Neurosci*. 2008 Apr;28(17):4336–49.
42. Pons M, Izquierdo I, Andreu-Carbò M, Garrido G, Planagumà J, Muriel O, et al. Phosphorylation of filamin A regulates chemokine receptor CCR2 recycling. *J Cell Sci*. 2017 Jan;130(2):490-501